Guidant Clarifies J&J Merger Terms, Incentives For Execs, Antitrust Defense

Antitrust regulators weighing the potential impact of a J&J/Guidant merger on the DES market are likely to be mollified by the number of firms with drug-eluting stents in development, Guidant CEO Ron Dollens says